Fulgent Genetics (FLGT) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fulgent Genetics (FLGT) has outperformed TriSalus Life Sciences (TLSI) over the past year, losing 8.8% versus a loss of 14.8%. Over five years, TLSI leads with a -58.3% price change compared with -73.3% for FLGT. Fulgent Genetics is the larger company by market cap ($598.2 million vs $250.0 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLGT | TLSI |
|---|---|---|
| Share price | $21.74 | $4.06 |
| Market cap | $598.18M | $249.99M |
| 1-day change | +4.42% | -1.69% |
| YTD return | -20.75% | -40.83% |
| 1-year return | -8.80% | -14.85% |
| 5-year return | -73.31% | -58.28% |
| EPS (TTM) | $-2.82 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.04 | $7.95 |
| 52-week low | $13.46 | $2.20 |
| Distance from 52-week high | -29.96% | -48.93% |
| Analyst consensus | none | none |
| Avg. price target upside | -12.60% | +156.16% |
| Average volume | 301.04K | 275.38K |
| Shares outstanding | 27.52M | 61.57M |
| Employees | 1,315 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Fulgent Genetics is about 2.4 times larger than TriSalus Life Sciences by market value ($598.18M vs $249.99M).
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Health Care · Medical Specialities · 1,315 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
FLGT vs TLSI FAQ
Which is bigger, Fulgent Genetics or TriSalus Life Sciences?
Fulgent Genetics (FLGT) is larger, with a market capitalization of $598.18M compared with $249.99M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, FLGT or TLSI?
FLGT returned -8.80% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are Fulgent Genetics and TriSalus Life Sciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.